Skip to main content
RXST
NASDAQ Industrial Applications And Services

RxSight 10-Q: Q3 Revenue Down 19% to $24.6M, $254.7M Cash, Alcon $50M Now Nonrefundable

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.92
Mkt Cap
$190.913M
52W Low
$4.4
52W High
$13.22
52W Position info
11% below low
Off High info
70% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

RXST is trading near its 52-week low of $4.4 (11% below the low).

Summary

RxSight's Q3 10-Q confirms revenue down 19% to $24.6 million and a $16.2 million net loss, backed by $254.7 million in cash, with the $50 million Alcon upfront now nonrefundable and LDD manufacturing paused on excess inventory.


Key Events · Earnings and Guidance · RXST

  • Q3 Revenue Falls 19% to $24.6M

    Total revenue of $24.6 million versus $30.3 million a year ago, driven by 23,128 LAL units and only 3 LDDs sold versus 25 in Q3 2025, reflecting competitive pressure.

  • Net Loss Widens to $16.2M

    Net loss of $(16.2) million, or $(0.39) per share, versus $(9.8) million, or $(0.24) per share, a year ago; gross margin slipped to 73.6% from 79.9% on higher inventory reserves.

  • Alcon $50M Becomes Nonrefundable

    The $50.0 million portion of the $60 million Alcon upfront payment lapsed its 120-day refund window on October 28, 2026 and will be added to the transaction price and allocated to performance obligations in Q4 2026.

  • Cash of $254.7M Funds 12 Months

    Cash, cash equivalents and short-term investments totaled $254.7 million at September 30, 2026; management states existing resources fund operations for at least the next 12 months.


Analysis · RXST · Industrial Applications And Services

The 10-Q confirms the weak quarter already reported in the concurrent 8-K, but its real value is the balance-sheet detail: $254.7 million of cash and investments against a $16.2 million quarterly net loss, and the $50.0 million Alcon upfront payment became nonrefundable on October 28, 2026, removing a refund liability from the balance sheet and adding $50 million to Q4 revenue to be recognized. Against that, the core business is shrinking — revenue fell 19% on 23,128 LAL units and only 3 LDDs sold versus 25 a year ago — and the company paused LDD manufacturing because inventory exceeds near-term demand, with reserves rising $1.8 million in the quarter. Management also ran an impairment test on long-lived assets after the market-cap decline and concluded no write-down was needed, a judgment call that would change if the stock and LDD demand stay weak.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RXST was trading at $3.92 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $190.9M. The 52-week trading range was $4.40 to $13.22. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RXST - Latest Insights

RXST
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.59
Real-time Price: $4.58 info
Change: -$0.0100 (-0.22%) info
Market Cap: $192.036M info
RXST
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.59
Real-time Price: $4.58 info
Change: -$0.0100 (-0.22%) info
Market Cap: $192.036M info
RXST
Aug 10, 2026, 8:01 AM EDT
Filing Type: SC TO-I
Importance Score:
7
Price at Filing: $6.26
Real-time Price: $4.58 info
Change: -$1.68 (-27%) info
Market Cap: $192.036M info
RXST
Jul 15, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.25
Real-time Price: $4.58 info
Change: -$0.670 (-13%) info
Market Cap: $192.036M info
RXST
Jul 06, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.54
Real-time Price: $4.58 info
Change: -$0.960 (-17%) info
Market Cap: $192.036M info